Invst LLC Increases Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Invst LLC boosted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 101.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,638 shares of the company’s stock after purchasing an additional 5,857 shares during the period. Invst LLC’s holdings in Amphastar Pharmaceuticals were worth $448,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. YHB Investment Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the 1st quarter valued at approximately $27,000. Innealta Capital LLC bought a new position in Amphastar Pharmaceuticals during the 2nd quarter valued at $55,000. Blue Trust Inc. grew its holdings in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares in the last quarter. nVerses Capital LLC increased its position in shares of Amphastar Pharmaceuticals by 37.5% in the 2nd quarter. nVerses Capital LLC now owns 2,200 shares of the company’s stock worth $88,000 after purchasing an additional 600 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at about $93,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AMPH. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, September 20th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $48.53 on Tuesday. The company has a market cap of $2.37 billion, a P/E ratio of 16.79, a PEG ratio of 0.92 and a beta of 0.82. The business has a 50 day moving average of $45.39 and a two-hundred day moving average of $42.71. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. The business had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. As a group, analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current year.

Insider Buying and Selling

In related news, CFO William J. Peters sold 10,282 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,162,175.69. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Rong Zhou sold 4,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the transaction, the executive vice president now directly owns 118,388 shares in the company, valued at approximately $5,724,059.80. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO William J. Peters sold 10,282 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,162,175.69. The disclosure for this sale can be found here. Insiders sold a total of 34,383 shares of company stock worth $1,524,123 in the last three months. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.